Menu
← Oncology Approval Tracker
FDA DECISION ·
Lanreotide injection (first generic)
lanreotide acetate · InvaGen Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First generic of the referenced lanreotide depot injection, including adults with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors and adults with carcinoid syndrome. The product also has an acromegaly indication.
LAMPGEN ANALYSIS
Why it matters
The product is relevant to both disease control and symptom management for neuroendocrine tumors.
What research teams should watch
Verify the selected strength and deep subcutaneous administration, and record whether the goal is tumor control or rescue therapy reduction.
PRIMARY RECORDS